Study calls for more cautious use of Tamiflu in children
This article was originally published in Scrip
Executive Summary
A study has found that treating influenza in children with Roche's antiviral Tamiflu (oseltamivir) or GlaxoSmithKline's rival drug Relenza (zanamivir) provides only a small improvement in the length of illness (between 0.5 and 1.5 days), casting doubt over their usefulness for the current pandemic.